Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Overactive Bladder Treatment Market by Pharmacotherapy & Disease Type - Global Forecast to 2022 - Research and Markets

Research and Markets
Posted on: 03 Aug 17

The "Overactive Bladder Treatment Market by Pharmacotherapy and Disease Type - Global Forecast to 2022" report has been added to Research and Markets' offering.

The global overactive bladder treatment market is estimated to grow at a CAGR of 2.9% from 2017 to 2022, to reach USD 4.19 billion by 2022. The key factors driving the growth of this market include the rising prevalence of overactive bladder (OAB) coupled with the growing geriatric population and rising neurological disorders, namely, Parkinson's Disease (PD), stroke, and multiple sclerosis (MS). However, the undesired systemic effects of current OAB treatments may hinder the growth of the market to a certain extent during the forecast period.

On the basis of pharmacotherapy, the overactive bladder treatment market is segmented into anticholinergics, mirabegron, BOTOX, and neurostimulation. The neurostimulation and BOTOX treatment segments are expected to witness the highest growth during the forecast period. The growth of these segments is mainly due to the higher efficacy and longevity of the treatment effects as compared to anticholinergics.

Based on anticholinergic drugs, the overactive bladder treatment market is further classified into darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, trospium, and other anticholinergics (imidafenacin, emepronium, flavoxate, meladrazine, terodiline, propiverine, and desfesoterodine). Solifenacin is expected to command for the largest share of the global overactive bladder treatment market owing to its efficacy as compared to other drugs of its class.

Companies Mentioned

  • Allergan, PLC.
  • Apotex Inc.
  • Astellas Pharma Inc.
  • Aurobindo Pharma Limited
  • Cogentix Medical, Inc.
  • Endo International PLC
  • Hisamitsu Pharmaceutical Co., Inc.
  • Intas Pharmaceuticals Ltd.
  • Johnson & Johnson
  • Macleods Pharmaceuticals Ltd.
  • Medtronic PLC
  • Mylan N.V.
  • Pfizer, Inc.
  • Sanofi
  • Teva Pharmaceutical Industries Limited

Key Topics Covered:

1 Introduction

2 Research Methodology

3 Executive Summary

4 Market Overview

5 Global Overactive Bladder Treatment Market, By Pharmacotherapy

6 Global Overactive Bladder Treatment Market, By Disease

7 Global Overactive Bladder Treatment Market, By Region

8 Marketed Products

9 Pipeline Products

10 Drug Profiles

11 Company Profiles

For more information about this report visit https://www.researchandmarkets.com/research/mqwgh9/overactive

View source version on businesswire.com: http://www.businesswire.com/news/home/20170803005586/en/

Business Wire
www.businesswire.com

Last updated on: 03/08/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.